We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




AI Predicts Pancreatic Cancer Three Years before Diagnosis from Patients’ Medical Records

By HospiMedica International staff writers
Posted on 10 May 2023
Print article
Image: AI model spots those at highest risk for up to three years before diagnosis (Photo courtesy of Freepik)
Image: AI model spots those at highest risk for up to three years before diagnosis (Photo courtesy of Freepik)

Screening for common cancers like breast, cervix, and prostate cancer relies on relatively simple and highly effective techniques, such as mammograms, Pap smears, and blood tests. These methods have revolutionized outcomes for these diseases by enabling early detection and intervention during the most treatable stages. However, pancreatic cancer screening is more challenging and costly. Physicians primarily consider family history and genetic mutations, which are important risk indicators but often overlook many patients. There is a need for a method that can expedite the diagnosis of pancreatic cancer, which is frequently found in advanced stages when treatment is less effective and outcomes are poor. Now, an artificial intelligence (AI) tool can successfully identify individuals at the highest risk for pancreatic cancer up to three years before diagnosis using only patients' medical records.

The findings of the new research led by investigators at Harvard Medical School (Boston, MA, USA; www.hms.harvard.edu) and the University of Copenhagen (Copenhagen, Denmark; www.ku.dk) suggest that AI-based population screening could be valuable for detecting those at increased risk for pancreatic cancer. Applied at scale, the AI tool could accelerate detection, lead to earlier treatment, and improve outcomes and extend patients' life spans. In the study, the AI algorithm was trained on two separate datasets totaling nine million patient records from Denmark and the U.S. The researchers "asked" the AI model to look for telltale signs based on the data contained in the records. Based on combinations of disease codes and their timing, the model was able to predict which patients are likely to develop pancreatic cancer in the future. Interestingly, many of the symptoms and disease codes were not directly related to or originating from the pancreas.

The researchers tested different versions of the AI models for their ability to detect people at elevated risk for disease development within different time scales — 6 months, one year, two years, and three years. Overall, each version of the AI algorithm was substantially more accurate at predicting who would develop pancreatic cancer than current population-wide estimates of disease incidence. The researchers believe the model is at least as accurate in predicting disease occurrence as current genetic sequencing tests, which are usually only available for a small subset of patients in datasets.

A significant advantage of the AI tool is that it can be used on any patient with available health records and medical history, not just those with known family history or genetic predisposition for the disease. This is particularly important because many high-risk patients may not be aware of their genetic predisposition or family history. Without symptoms and a clear indication of high risk for pancreatic cancer, clinicians may be hesitant to recommend more sophisticated and expensive testing, such as CT scans, MRI, or endoscopic ultrasound. When these tests are used and suspicious lesions discovered, the patient must undergo a procedure to obtain a biopsy. An AI tool that identifies those at the highest risk for pancreatic cancer would ensure that clinicians test the right population while sparing others unnecessary testing and additional procedures, according to the researchers.

“One of the most important decisions clinicians face day to day is who is at high risk for a disease, and who would benefit from further testing, which can also mean more invasive and more expensive procedures that carry their own risks,” said study co-senior investigator Chris Sander, faculty member in the Department of Systems Biology in the Blavatnik Institute at HMS. “An AI tool that can zero in on those at highest risk for pancreatic cancer who stand to benefit most from further tests could go a long way toward improving clinical decision-making.”

“Many types of cancer, especially those hard to identify and treat early, exert a disproportionate toll on patients, families and the healthcare system as a whole,” said study co-senior investigator Søren Brunak, professor of disease systems biology and director of research at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. “AI-based screening is an opportunity to alter the trajectory of pancreatic cancer, an aggressive disease that is notoriously hard to diagnose early and treat promptly when the chances for success are highest.”

Related Links:
Harvard Medical School 
University of Copenhagen 

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Oxygen Concentrator
ZH-A51
New
Mobile Barrier
Tilted Mobile Leaded Barrier

Print article

Channels

Critical Care

view channel
Image: The AI-powered algorithm offers quick, no-contact screenings for high blood pressure and diabetes (Photo courtesy of 123RF)

AI-Powered Algorithm Offers Quick, Contactless Blood Pressure and Diabetes Screening

A newly developed system that combines high-speed video with an artificial intelligence (AI)-powered algorithm may provide a quick, non-contact method for screening high blood pressure and Type 1 or Type... Read more

Surgical Techniques

view channel
Image: Catheters coated with the new material showed a significant reduction in clotting on the device surface (Photo courtesy of UBC Faculty of Medicine)

Newly Developed Coating Makes Medical Devices Clot-Free

Thrombosis, or the formation of blood clots, presents a significant challenge for devices that come into contact with blood. Unlike natural blood vessels, these devices can activate specific proteins in... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.